AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04426006 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PRO-SERO-COV
Description: At inclusion, 3 months and 12 months :~* blood sample (2 x 5ml)~* self-administered questionnaire
Study NCT01015014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AN3365
Description: LP, 600 mg vial; reconstituted in Normal Saline
Study NCT01015014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride for injection
Study NCT01515345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prasugrel or ticagrelor
Description: prasugrel 10mg od for 12 month ticagrelor 90mg td for 12 month
Study NCT01515345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: clopidogrel 75mg od for 12 month
Study NCT05697939 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: NSite 3D Scanning
Description: Three separate users will enter the exam room and use the NSite application to scan the patient in the bending position. These users may include research coordinators, physicians, or other authorized staff.~The NSite application will have a user tutorial on how to scan patients that users are instructed to watch prior to conducting a scan.~All participants are asked to remove clothing above the waist but may keep a bra or tight-fitting shirt on during the scanning procedures. The patient will be asked to assume a forward bending position. One user will capture a scan of the patient's back in this position. The user will calibrate the device and then walk around the patient while scanning per app directions. Once this user captures the scan, it will be processed by the application. New scans will then be obtained by the two other users. Once all users have captured a scan, the scanning process and patient participation will be completed.
Study NCT00003384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical Papanicolaou Test
Description: Undergo Pap smear
Study NCT00003384 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conization
Description: Undergo cone biopsy
Study NCT00003384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00209274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous mitral valve repair using MitraClip implant
Description: MitraClip Implant
Study NCT00209274 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mitral valve repair or replacement surgery
Description: Repair or replacement of mitral valve
Study NCT03074110 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Isocapnic hyperventilation
Description: Mechanical hyperventilation to enhance elimination of inahalation anesthetics. Administration of a precalculated flow of CO2 according to gender and weight into the inspiratory limb of the breathing circuit in order to avoid hypocapnia.
Study NCT01726686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 100 ml Ropivacaine 10mg/ml in a continuous infusion pump set at 2 ml/hour
Study NCT01726686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02233153 — intervention group
Intervention type: OTHER
Intervention: Elder-Friendly Surgical Unit
Study NCT01776203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medroxyprogesterone 17-Acetate
Description: MPA pills 20 mg (2 X 10 mg) twice daily for 3 weeks
Study NCT01016002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temoporfin
Description: Drug treatment: Temoporfin 0.15 mg/kg body weight, intravenous injection within at least 6 min.~Laser Treatment: 652nm wavelength; 30 Joules/cm diffusor length ( 200 sec at 150mW/cm diffusor length), within 96 h after Foscan
Study NCT01363271 — intervention group
Intervention type: DRUG
Intervention: Linezolid
Description: IV and oral forms of linezolid are identified through a pre-specified list of National Drug Codes (NDCs).
Study NCT01346670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LipoCol and Mevacor
Description: To evaluate the relative bioavailability of lovastatin and its ß-hydroxy acid of 600 mg LipoCol Forte® Capsules compared to that of one 20 mg Mevacor® Tablet after single oral administration in healthy subjects using a 2x2 crossover design.
Study NCT02753530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arimoclomol
Description: 2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily during breakfast, early afternoon, and at bedtime
Study NCT02753530 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 matched placebo capsules taken 3 times daily during breakfast, early afternoon, and at bedtime
Study NCT03958630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-ER176
Description: PET biomarker for inflammation
Study NCT01363271 — intervention group
Intervention type: DRUG
Intervention: Vancomycin
Description: IV form of vancomycin is identified through a pre-specified list of National Drug Codes (NDCs).
Study NCT03958630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-PIB
Description: PET biomarker for amyloid
Study NCT03422718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Behavior Texts
Description: Participants receive motivational health behavior texts
Study NCT03422718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No healthy behavior texts
Description: Participants do not receive healthy behavior texts
Study NCT03422718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BP Monitoring Daily Via Text Messaging
Description: Daily text messages will prompt participants for BP by home cuff
Study NCT03422718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BP Monitoring Weekly Via Text Messaging
Description: Weekly text messages will prompt participants for BP by home cuff
Study NCT03422718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician appointment and transportation scheduling
Description: Participants receive assistance scheduling physician appointment and transportation to those appointments
Study NCT03422718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No physician appointment and transportation scheduling
Description: Participants do not receive assistance scheduling physician appointment or transportation
Study NCT00849212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2007
Description: The dose of E2007 will start from 2 mg and will be increased by 2 mg every week up to 12 mg (the maximum dose). The dose will be adjusted during 6 weeks (i.e., titration period). Subsequently, the dose will be fixed and maintained during 4 weeks (Maintenance period). Patients must visit study site at Weeks -4, 1, 2, 3, 4, 5, 6, 8, 10 and 14 to confirm.
Study NCT00579904 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: walnuts
Description: Subjects will follow their usual diet for 4 weeks; after that they will be randomized to walnuts. They will eat walnuts once daily for six weeks.
Study NCT00579904 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: almonds
Description: Subjects will follow their usual diet for 4 weeks; after that they will be randomized to almonds. They will eat almonds once daily for six weeks.
Study NCT04501575 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Consultation
Description: A consultation including case history taking, physical assessment, osteopathic manual treatment, exercise prescription, and postural advice.
Study NCT04501575 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Osteopathic Consultation
Description: A sham treatment using light touch on bony structures, no diagnosis, advise or prescriptions
Study NCT02227264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: Cinacalcet, Mimpara® 30mgx1-2 for 4 weeks
Study NCT02227264 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: parathyroid adenomectomy
Description: surgical removal of pathologic parathyroid tissue
Study NCT02510482 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT02636491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MD-Logic-Automated Insulin Delivery System
Description: Subjects will undergo 60 hours at home under MD-Logic control and continuing with their regular routine life. At evening of the first intervention day patients will switch to MD-Logic control. Patients will be asked to connect study sensor and pump to the computer using the MD-Logic software. After the activation of the MD-Logic system, basal insulin dosing and correction boluses will be fully automated and controlled by the MD-Logic system except to meal boluses. Patients will be encouraged to measure capillary blood glucose at least 4 times a day, before each meal and before bed time. After the third night the patient will turn the closed-loop controller OFF, this will automatically save the log file. The patient will return to his regular insulin treatment.
Study NCT02636491 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MiniMed Paradigm® Veo™ System
Description: Subjects use 60 hours at home their conventional insulin pump and continuing with their regular Routine life. During this therapy the Insulin pump operating separately and are not controlled by the MD-Logic System.
Study NCT04545138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive training combine treadmill training
Description: Treadmill training includes warming up for 3 minutes, training for 25 minutes, and relaxing for 2 minutes. The speed of the treadmill during the warm-up and relaxation period is based on the participant's Borg's rating of perceived exertion (RPE) 7-9 points (very slight to very slight), and the RPE during the training period does not exceed 10\~12 points (slight), and ensures that patients can be cognitively trained at the same time. The cognitive training tasks will be projected on the screen and the participant have to answer the task orders during treadmill training simultaneously.
Study NCT04545138 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill training
Description: Treadmill training includes warming up for 3 minutes, training for 25 minutes, and relaxing for 2 minutes. The speed of the treadmill during the warm-up and relaxation period is based on the participant's Borg's rating of perceived exertion (RPE) 7-9 points (very slight to very slight), and the RPE during the training period does not exceed 10\~12 points (slight).
Study NCT03159949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REHIIT
Description: REHIIT participants will come into the lab one time per training days (3 training days per week), each session lasting 10 minutes. Training sessions involve a two-minute warm-up, 3 X 20-second cycling sprints on an exercise bike with three minutes rest in between, and a one-minute cool-down.
Study NCT00542828 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thymoglobulin®, Rabbit Anti-thymocyte Globulin (rATG)
Description: All patients were to be treated with rATG 3.75 mg/kg/day administered by intravenous (IV) infusion over ≥6 hours for 5 consecutive days (cumulative dose: 18.75 mg/kg)
Study NCT03159949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PR-REHIIT
Description: PR-REHIIT participants will come into the lab on 3 separate occasions on the training days, which occur 3 days per week (i.e., 9 sessions per week). Each session lasts 3 minutes and 20 seconds and consists of a two-minute warm-up, a 20-second all-out sprint on a cycle ergometer, and a one-minute cool-down. There will be 1-4 hours of rest in between training sessions where participants are free to leave the lab and go about their normal day.
Study NCT02409901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Rehabilitation
Description: 12 month personalized exercise rehabilitation in addition to standard clinical care
Study NCT04122495 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Oral administration of B. lactis M8 at 10 log CFU/day for 4-weeks
Study NCT04122495 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of maltodextrin daily for 4-weeks
Study NCT03165903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cue and Implementation Intention-Based Intervention
Description: Families from a school assigned to Cue and Implementation Intention-Based Intervention received an intervention targeting increased levels of healthy snacking and reduced levels of sugar sweetened beverage consumption. The intervention consisted of a 90-minute meeting with a trained Health Coach, two 20-minute phone calls, 4 tailored newsletters, and a series of emails and text messages. Cues for snacking and sweetened beverage consumption were removed or relocated and implementation-intentions were created to trigger alternative behaviors to snacking and sweetened beverage consumption in the presence of cues. Both interventions were delivered over 3-10 weeks depending on the self-directed pace of the participants. All participants completed a follow-up assessment 3 months after consent.
Study NCT03165903 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control arm
Description: Families that were from a school assigned to Control received an intervention on sun safety that consisted of a 10-minute meeting with a trained Health Coach, 2 generic newsletters, an email, and a text message. Both interventions were delivered over 3-10 weeks depending on the self-directed pace of the participants. All participants completed a follow-up assessment 3 months after consent.
Study NCT01137812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100 mg
Description: One 100 mg capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
Study NCT01137812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Description: One 300 mg capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
Study NCT01137812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patients will continue to take background therapy with Metformin for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study.
Study NCT01137812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Patients will continue to take background therapy with Metformin for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study.
Study NCT01137812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulphonylurea
Description: Patients will continue to take background therapy with Sulphonylurea for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study.
Study NCT01137812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulphonylurea
Description: Patients will continue to take background therapy with Sulphonylurea for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study.
Study NCT04261595 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dates fruit as functional Food
Description: Two groups will receive Dates; The number per group is dependant on the child age. For children aged 3-6 years; they will receive the minimum numbers of dates (3 pieces). For children aged more than 6-12 years will receive 5 pieces of Dates the choice of the minimum numbers of dates (3 pieces) in this current trial is based on a study that was done by Al Jaouni and his colleagues, 2019 which proved the effects of three pieces of Ajwa on infection, hospitalization, and survival among 26 pediatric cancer patients in a university hospital; for which their treatment outcome was improved due to their intake of this amount of Ajwa during their standard treatment
Study NCT04261595 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: behavioral modification and stimulation
Description: Behavioral modification applied to the autistic children that is based on applied behavior analysis (ABA), a widely accepted approach that tracks a child's progress in improving his or her skills. We use Positive Behavioral and Support (PBS)
Study NCT04261595 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nutritional Guidance
Description: The nutritional education sessions are based on educating parents on providing their autistic children with a nutritious, balanced diet. Because children with ASD often have restricted diets as well as difficulty sitting through meal times, they may not be getting all the nutrients they need, particularly calcium and protein
Study NCT01843556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2022 Tape Formulation
Description: E2022 tape formulation applied to different application sites and at different intervals in Japanese healthy elderly males
Study NCT00947102 — intervention group
Intervention type: OTHER
Intervention: Observation
Study NCT00749086 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balloon kyphoplasty
Description: Balloon Kyphoplasty, a variant of Vertebroplasty, in which a balloon is first placed into the fractured vertebra and inflated with fluid in order to create a cavity. Then, the balloon are deflated and removed. This may restore part of the vertebral height loss due to the fracture and facilitate the injection of the cement with low pressure.
Study NCT00749086 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vertebroplasty
Description: Vertebroplasty consisting in the percutaneous injection into the fractured vertebra of polymethylmetacrylate cement (the cement used to fix prosthesis in joint replacement) through a posterior route through the vertebral pedicles under radiological guidance
Study NCT03759652 — intervention group
Intervention type: BEHAVIORAL
Intervention: before-after study
Description: The data analysed involve the time when the targeted, active surveillance of infections was establised, initially: 2003-2017, using tools (definitions, protocols) in accordance with the National Healthcare Safety Network (NHSN), then from 2012, HAI recognition methodology and HAI record-keeping has followed the Surveillance Network (HAI-Net), European Centre for Disease Prevention and Control (ECDC).
Study NCT02334267 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: GranuFlo
Description: Study subjects will be randomized to undergo dialysis treatments using GranuFlo, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using NaturaLyte, a commercially available acid dialysate concentration for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
Study NCT02334267 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group 2: NaturaLyte
Description: Study subjects will be randomized to undergo dialysis treatments using NaturaLyte, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using GranuFlo, a commercially available acid dialysate concentration for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
Study NCT01793987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coblation polypectomy
Study NCT01090557 — intervention group
Intervention type: OTHER
Intervention: Collection of exhaled breath
Description: balloon collection, via the tidal breathing techniques with uncontrolled flow rate for offline feNO measurement
Study NCT03744689 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane block
Description: Erector Spinae plane block will be done according to hernia level using bupivacaine hydrochloride
Study NCT03744689 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham block
Description: Sham block will be done with serum physiologic.
Study NCT03744689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 20 ml 0,25% Bupivacaine will be used for block performances
Study NCT03744689 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PCA
Description: Intravenous morphine patient controlled analgesia device will be given to the patients postoperatively and 24 hour morphine consumption will be recorded
Study NCT03744689 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCA
Description: Intravenous morphine patient controlled analgesia device will be given to the patients postoperatively and 24 hour morphine consumption will be recorded
Study NCT01416311 — intervention group
Intervention type: DRUG
Intervention: Eltrombopag
Study NCT02788539 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Our Whole Lives Website
Description: OWL is a nine-session, web accessible, self-paced curriculum that has interactive components of self-monitoring and social support (online community).
Study NCT02660697 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extraction site development
Description: In the test group, extraction sockets presenting EDS Type 3-4 buccal bony dehiscences were treated by a novel minimally invasive tunnelised modified GBR approach (XSD).
Study NCT03026517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Study NCT03026517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Study NCT03026517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenformin